Current Neuropharmacology
Volume 17, 12 Issues, 2019
ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)
This journal supports open access
ISSN: 1875-6190 (Online)
ISSN: 1570-159X (Print)
This journal supports open access
Ranking and Category
-
59th of 267 in
Neurosciences
-
33rd of 267 in
Pharmacology & Pharmacy
Contents
Current Neuropharmacology, Volume 13 - Number 6
Editorial
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
, 13(6): 739 - 749Won Je Jeon, Brian Dean, Elizabeth Scarr and Andrew Gibbons
DOI: 10.2174/1570159X13666150612230045
The Role of Muscarinic Receptors in the Pathophysiology of Mood Disorders:A Potential Noveltreatment?
Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
, 13(6): 750 - 759Jung Suk Lee, Suwon Jung, Il Ho Park and Jae-Jin Kim
DOI: 10.2174/1570159X13666150612230333
Neural Basis of Anhedonia and Amotivation in Patients with Schizophrenia: The Role of Reward System
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
, 13(6): 760 - 775Shintaro Ogawa and Hiroshi Kunugi
DOI: 10.2174/1570159X13666150612225212
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants
Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
, 13(6): 776 - 785Kunio Yui, George Imataka, Hiroyuki Nakamura, Naoki Ohara and Yukiko Naito
DOI: 10.2174/1570159X13666151102103305
Eicosanoids Derived From Arachidonic Acid and Their Family Prostaglandins and Cyclooxygenase in Psychiatric Disorders
Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3
, 13(6): 786 - 792Shigeo Uchino and Chikako Waga
DOI: 10.2174/1570159X13666151029105547
Novel Therapeutic Approach for Autism Spectrum Disorder: Focus on SHANK3
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
, 13(6): 793 - 801Takashi Uehara, Tomiki Sumiyoshi and Masayoshi Kurachi
DOI: 10.2174/1570159X13666151009120153
New Pharmacotherapy Targeting Cognitive Dysfunction of Schizophrenia via Modulation of GABA Neuronal Function
The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
, 13(6): 802 - 814Arqam Qayyum, Clement C. Zai, Yuko Hirata, Arun K. Tiwari, Sheraz Cheema, Behdin Nowrouzi, Joseph H. Beitchman and L. Kennedy
DOI: 10.2174/1570159X13666150612225836
The Role of the Catechol-o-Methyltransferase (COMT) GeneVal158Met in Aggressive Behavior, a Review of Genetic Studies
The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
, 13(6): 815 - 818Antonio Siniscalchi, Antonello Bonci, Nicola Biagio Mercuri, Domenico Pirritano, Aida Squillace, Giovambattista De Sarro and Luca Gallelli
DOI: 10.2174/1570159X13666150729222643
The Role of Topiramate in the Management of Cocaine Addiction: a Possible Therapeutic Option
Use of Push-Pull Superfusion Technique for Identifying Neurotransmitters Involved in Brain Functions: Achievements and Perspectives
, 13(6): 819 - 829Michaela M. Kraus and Athineos Philippu
DOI: 10.2174/1570159X13666150722233149
Use of Push-Pull Superfusion Technique for Identifying Neurotransmitters Involved in Brain Functions: Achievements and Perspectives
An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa
, 13(6): 830 - 835Shu-ichi Kojima, Atsushi Tohei, Masashi Ikeda and Naohiko Anzai
DOI: 10.2174/1570159X13666150825220524
An Endogenous Tachykinergic NK2/NK3 Receptor Cascade System Controlling the Release of Serotonin from Colonic Mucosa
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
, 13(6): 836 - 844Iwona Gagalo, Izabela Rusiecka and Ivan Kocic
DOI: 10.2174/1570159X13666150518235504
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Erratum
  |
Editor-in-Chief
T.E. Salt
University College London
Institute of Ophthalmology
London EC1V9EL
UK
Biography
View Full Editorial Board
University College London
Institute of Ophthalmology
London EC1V9EL
UK
Biography
Biography of T.E. Salt
Professor Tom Salt obtained his Degrees from The Universities of Cambridge and Bristol, is co-founder and Director of Neurexpert Ltd, and Emeritus Professor at University College London. He has worked in the pharmaceutical industry, and acted as a consultant and adviser to industry.
Professor Salt's research encompasses the pharmacology of neurotransmitters in relation to the sensory system systems, and more recently the functional consequences of neurodegeneration. He has published over 200 research and review papers, and is a member of several editorial boards and Editor in Chief of "Current Neuropharmacology"
About the Journal
For Authors
For Librarians & Readers
Journal History
Current Neuropharmacology was introduced in 2003 with the assistance of Dr. T.E. Salt, who is the current Editor-in-Chief serving since 2003.
Scopus CiteScore Metrics: 2.17
New eBook
 |
Neurobiology of Mood DisordersYou can view the contents of this eBook [here] or purchase it [here]. |
Webmaster Contact: info@benthamscience.net